Combining brentuximab vedotin with ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
Auteur(s) :
Kersten, M. J. [Auteur]
Driessen, J. [Auteur]
Zijlstra, J. M. [Auteur]
Plattel, W. J. [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Lugtenburg, P. J. [Auteur]
Brice, P. [Auteur]
Hutchings, M. [Auteur]
Gastinne, T. [Auteur]
Liu, R. [Auteur]
Burggraaff, C. N. [Auteur]
Nijland, M. [Auteur]
Tonino, S. H. [Auteur]
Arens, A. I. J. [Auteur]
Valkema, R. [Auteur]
Van Tinteren, H. [Auteur]
Lopez-Yurda, M. [Auteur]
Diepstra, A. [Auteur]
De Jong, D. [Auteur]
Hagenbeek, A. [Auteur]
Driessen, J. [Auteur]
Zijlstra, J. M. [Auteur]
Plattel, W. J. [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Lugtenburg, P. J. [Auteur]
Brice, P. [Auteur]
Hutchings, M. [Auteur]
Gastinne, T. [Auteur]
Liu, R. [Auteur]
Burggraaff, C. N. [Auteur]
Nijland, M. [Auteur]
Tonino, S. H. [Auteur]
Arens, A. I. J. [Auteur]
Valkema, R. [Auteur]
Van Tinteren, H. [Auteur]
Lopez-Yurda, M. [Auteur]
Diepstra, A. [Auteur]
De Jong, D. [Auteur]
Hagenbeek, A. [Auteur]
Titre de la revue :
Haematologica
Numéro :
106
Pagination :
1129-1137
Date de publication :
2020-04-11
ISSN :
1592-8721
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem-cell transplant (auto-PBSCT) predicts progression free survival (PFS) in relapsed/refractory classical ...
Lire la suite >Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem-cell transplant (auto-PBSCT) predicts progression free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL). We added brentuximab vedotin (BV) to DHAP to improve the mCR rate. In a Phase I dose-escalation part in 12 patients, we showed that BV-DHAP is feasible. This Phase II study included 55 R/R cHL patients (23 primary refractory). Treatment consisted of three 21-day cycles of BV 1.8 mg/kg on day 1, and DHAP (dexamethasone 40mg days 1-4, cisplatin 100mg/m2; day 1 and cytarabine 2x2g/m2; day 2). Patients with a metabolic partial response (mPR) or mCR proceeded to HDC/auto-PBSCT. Based on independent central FDG-PET-CT review, 42 of 52 evaluable patients (81% [95% CI: 67-90]) achieved an mCR before HDC/auto-PBSCT, five had an mPR and five had progressive disease (three were not evaluable). After HDC/auto-PBSCT, four patients with an mPR converted to an mCR. The 2-year PFS was 74% [95% CI: 63-86], and the overall survival 95% [95% CI: 90-100]. Toxicity was manageable and mainly consisted of grade 3/4 hematological toxicity, fever, nephrotoxicity, ototoxicity (grade 1/2) and transiently elevated liver enzymes during BV-DHAP. Eighteen patients developed new onset peripheral neuropathy (maximum grade 1/2) and all recovered. In conclusion, BV-DHAP is a very effective salvage regimen in R/R cHL patients, but patients should be monitored closely for toxicity. ClinicalTrials.gov identifier: NCT02280993.Lire moins >
Lire la suite >Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem-cell transplant (auto-PBSCT) predicts progression free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL). We added brentuximab vedotin (BV) to DHAP to improve the mCR rate. In a Phase I dose-escalation part in 12 patients, we showed that BV-DHAP is feasible. This Phase II study included 55 R/R cHL patients (23 primary refractory). Treatment consisted of three 21-day cycles of BV 1.8 mg/kg on day 1, and DHAP (dexamethasone 40mg days 1-4, cisplatin 100mg/m2; day 1 and cytarabine 2x2g/m2; day 2). Patients with a metabolic partial response (mPR) or mCR proceeded to HDC/auto-PBSCT. Based on independent central FDG-PET-CT review, 42 of 52 evaluable patients (81% [95% CI: 67-90]) achieved an mCR before HDC/auto-PBSCT, five had an mPR and five had progressive disease (three were not evaluable). After HDC/auto-PBSCT, four patients with an mPR converted to an mCR. The 2-year PFS was 74% [95% CI: 63-86], and the overall survival 95% [95% CI: 90-100]. Toxicity was manageable and mainly consisted of grade 3/4 hematological toxicity, fever, nephrotoxicity, ototoxicity (grade 1/2) and transiently elevated liver enzymes during BV-DHAP. Eighteen patients developed new onset peripheral neuropathy (maximum grade 1/2) and all recovered. In conclusion, BV-DHAP is a very effective salvage regimen in R/R cHL patients, but patients should be monitored closely for toxicity. ClinicalTrials.gov identifier: NCT02280993.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Date de dépôt :
2023-05-25T03:37:54Z
2023-09-15T11:37:40Z
2023-09-15T11:37:40Z